CoChat

Treatment-resistant depression: recent developments and future directions

Open access
Mathew, Sanjay J. · 2008 · Depression and Anxiety
Cited by 51

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

A significant proportion of patients with major depressive disorder (MDD) fail to achieve remission with standard antidepressant therapies, even when optimally delivered. These patients are classified as treatment-resistant depression (TRD), which is distinguished from "difficult-to-treat" depression,1 defined as depression treated under circumstances that precludes the optimal delivery of a potentially beneficial treatment (e.g., subtherapeutic dosing, intolerable side effects, poor adherence, etc.) TRD is also distinguished from severe depression, as some patients with milder depressive symptoms are markedly treatment resistant, whereas others with profound, acute depressive symptoms are quite treatment responsive. Defining the boundaries of TRD is critical from a clinical, research, and public health perspective, as drug and device manufacturers seek new regulatory approvals for numerous indications in the TRD spectrum. This article reviews recent developments in TRD, with a focus on classification methods used for regulatory clinical trials; treatments currently approved in the US for TRD; how classification schemes and regulatory rules have limited understanding of their scope of effectiveness; and what changes are needed in research approaches to facilitate novel therapeutic discovery. There is no validated consensus definition of TRD. At a minimum, TRD signifies depression that has failed to respond to at least one optimally administered therapy. Regulatory authorities such as the European Agency for the Evaluation of Medicinal Products have defined TRD as failure to respond to two products of different classes, used for a sufficient length of time at an adequate dose, without specification of an adequate dose or duration.2 The US FDA does not define TRD. Rather, FDA approved devices or medication describe the specific patient population investigated in pivotal trials demonstrating safety and efficacy. Several rating instruments and classification schemes for treatment resistance have been adopted for use in research studies of TRD, although none are routinely used in clinical settings. At a minimum, these instruments attempt to quantify the number of previous antidepressant trials (including augmentation strategies and electroconvulsive therapy; ECT), assess the adequacy of trials by determining maximum dose and duration, and assess patients' response to treatments.3 Although several instruments have shown reliability and validity in research settings, they have important limitations: (1) Four to six-week monotherapy trials of antidepressants may be categorized as adequate, despite evidence that longer trial durations may be required, particularly for chronic depressions; (2) acceptable antidepressant doses in previous trials include the minimal approved dose, although drugs such as venlafaxine XR may require titration significantly higher than approved doses;4 (3) most critically, the infrequent implementation of measurement-based care5 in clinical practice obstructs the accurate determination of response to previous therapies. Further, the lack of electronic medical records in most treatment settings hinders researchers' ability to obtain records in a timely and efficient manner earlier to study enrollment. Even when obtained, medical records may be difficult to interpret due to incomplete documentation of response, side effects, adherence, and concurrent therapies (psychotherapy, phototherapy, etc.). Salient clinical issues impacting outcome in MDD such as substance use and exercise may be unrecorded. Thus, the validity of TRD may ultimately hinge on the accuracy of patients' self-report of their complex treatment histories and clinical course. Five treatments have received regulatory approval in the US for TRD, including three devices [ECT, vagus nerve stimulation (VNS), transcranial magnetic stimulation (TMS)], one medication (the atypical antipsychotic aripiprazole), and one medicinal food (l-methylfolate). In addition, two industry-supported pivotal trials of deep brain stimulation (DBS) are ongoing, and several pharmacotherapies are expected to seek regulatory approval in the next few years. Although each of these treatments has been studied in patients who meet a broad categorical definition of TRD, the heterogeneity of the specific patient populations and study designs make it difficult to directly compare these therapies. Most recently in October 2008, the Center for Devices and Radiological Health (CDRH) of the FDA approved the NeuroStar TMS system as monotherapy for MDD patients who failed to respond to one earlier antidepressant medication at or above the minimal effective dose and duration in the current episode. In 2007, aripiprazole was approved on the basis of two positive, 6-week placebo-controlled trials in MDD patients who showed an insufficient response to 2–4 courses of an antidepressant medication (of which one trial was conducted prospectively for 8 weeks). VNS was approved

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/da.20540

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 51

Metadata

Authors
Mathew, S. J.
Venue
Depression and Anxiety
Published
2008-12
Volume
25
Issue
12
Pages
989-992
ISSN
  • 1091-4269 (ISSN-L)
  • 1520-6394
OpenAlex
W1998997980
Cited by
51
References
6
FWCI
2.48
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.